A Big Ten Cancer Research Consortium trial, BTCRC-LUN20-462, titled, “A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study,” was presented as a poster presentation at the 2024 American Society of Hematology Annual Meeting on December 9, 2024.
Congratulations to Vaishalee P Kenkre, MD, of the University of Wisconsin School of Medicine and Public Health, Andrew M Evens, DO, MBA, MSc, of Rutgers Cancer Institute and all co-authors!
December 6, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) trial titled, “A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042” has been accepted as a poster presentation (P2-07-21) at the 2024 San Antonio Breast Cancer Symposium on December 11, 2024 from 5:30 pm – 7:30 pm. Congratulations to all co-authors and study teams involved in the study! Read More
December 4, 2024: A Big Ten Cancer Research Consortium trial titled, “Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409)” has been accepted for a poster presentation at the 2024 San Antonio Breast Cancer Symposium on December 11, 2024 from 5:30 pm – 7:00 pm. Congratulations to all co-authors and study teams involved in the study! Read More
December 2, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) study, BTCRC-LUN16-081, led by Greg Durm, MD, of IU Simon Comprehensive Cancer Center, was published in the Journal of Thoracic Oncology in October 2024. The article is titled, “Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.” Congratulations to all co-authors and study teams whose hard work led to this publication. Read More
October 1, 2024: The Big Ten Cancer Research Consortium (Big Ten CRC) congratulates Kari Wisinski, MD, on receiving the 2024 Pat Loehrer Award for Exemplary Collaboration in Cancer Research. Read More
October 10, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) study, BTCRC-GI15-015, led by Al B. Benson III, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was published in The Oncologist on September 18, 2024. The article is titled, “A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial.” Congratulations to all co-authors and study teams whose hard work led to this publication. Read More
October 1, 2024: The Big Ten Cancer Research Consortium (Big Ten CRC) is pleased to announce the release of a Request for Applications (RFA) for its 2025 Kenneth and Verna Mae Jessen Award. This award will provide $65,000 in funding. It is expected that 100% of the award will support direct research costs. The Big Ten CRC Foundation will provide up to 10% overhead (F&A) from other funding sources. The Big Ten CRC Foundation established the Kenneth and Verna Mae Jessen Award to support basic, correlative, clinical, or population science oncology research based at a Big Ten CRC institution. The award is made possible through the generous support of the Verna Mae Jessen Trust. The Jessen family’s passion for oncology research stems from their long history with cancer. Several members of the family, including... Read More
September 4, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) study manuscript was published in Lung Cancer Journal on August 15, 2024. The article is titled, “Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.” Congratulations to all co-authors and study teams whose hard work led to this publication. Read More
August 12, 2024: The Big Ten Cancer Research Consortium is happy to celebrate the research accomplishments of our members over the past year. Congratulations to all researchers and study teams whose hard work produced eight journal manuscripts and meeting abstracts between July 1, 2023, and June 30, 2024! Read More
August 2, 2024: The expansion of the Big Ten Conference on August 2 to include four new members creates an opportunity for growth of the Big Ten Cancer Research Consortium (Big Ten CRC). The Big Ten CRC has invited the new members of the athletic conference – the University of California at Los Angeles, the University of Oregon, the University of Southern California, and the University of Washington – to join the Big Ten CRC. Plans to expand the Big Ten CRC are proceeding. Read More
A Big Ten Cancer Research Consortium trial, BTCRC-LUN20-462, titled, “A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study,” was presented as a poster presentation at the 2024 American Society of Hematology Annual Meeting on December 9, 2024. 
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube